Therefore, a small molecule inhibitor of AXL, bemcentinib, which selectively binds to the intracellular catalytic kinase domain of AXL, is a licensed therapy currently in multiple Phase II trials for the treatment of breast, lung, and myeloid neoplasms (10–12). Here, AXL is linked to myeloid neoplasm.